SURGICALLY TARGETED RADIATION THERAPY FOR PATIENTS WITH OPERABLE BRAIN TUMORS

Right Treatment. Right Time. Right Place.

GammaTile Therapy is a Surgically Targeted Radiation Therapy 

(STaRT) that provides immediate, dose-intense treatment at the completion of resection. By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy can extend local

recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.[1]

 

Elevating Outcomes With Optimized Dosimetry

GammaTile Therapy vs Intensity-Modulated Radiation Therapy (IMRT)

GammaTile is designed with uniform radiation-source spacing to ensure an even dose distribution. The favorable depth-dose profile optimizes local tumor control.[2]

The colors indicate the radiation location and intensity from the 2 types of treatment. Blue-green indicates lower radiation levels. Red indicates higher levels. The extracranial dose is likely lower than shown, as the planning system did not utilize inhomogeneity corrections.

Advancing Safety

Designed with the brain’s delicate environment in mind to limit radiation changes in healthy tissue[1]

* Defined as common terminology criteria for adverse events (CTCAE), Grade 3–5 possibly or probably related to GammaTile Therapy placement occurring at any time during follow-up.

 
 

How It Works. An Eloquent Solution.

GammaTile Therapy targets tumor cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.[1]

 

Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment. 

Enhanced local control and optimized efficacy[1]

  • 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.[7]

  • 88% of the therapeutic dose is delivered within 30 days, with more than 95% of the dose delivered by 6 weeks.[7]

  • A favorable depth-dose profile optimizes local tumor control.[2]

Cesium-131 Distribution and Intensity
Bioresorbable, conformable collagen tile preserves healthy tissue 
  • Provides a structural offset of the radiation source from normal brain tissue

  • Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles

  • Minimizes local hot and cold spots

  • Facilitates rapid, accurate placement to deliver a predictable radiation dose

Uniform Radiation Source,

Structurally Offset Design

2-cm height  |  2-cm width  |  4-mm thickness

What I like about GammaTile is that they’re taking a radiation technology that already exists and making it safer and easier to deliver… [It] should be equally effective and faster to implant after tumor surgery…[It’s] better for patients (with less anesthesia time) and safer for the staff (with less exposure in the OR).

  Dr Helen Shih  

Radiation Oncologist at Massachusetts General Hospital

 

GammaTile Therapy Webinars

Watch an in-depth educational webinar about GammaTile Therapy, presented by world-renowned neurosurgeon Dr Joseph Zabramski and hosted by The Musella Foundation. Content includes background, safety and efficacy, surgical placement, a case study, and clinical trial information. Watch here

This American Brain Tumor Association patient webinar provides a detailed overview of surgically implanted brain tumor therapies, including GammaTile Surgically Targeted Radiation Therapy (STaRT). Dr John A. Boockvar, the director of the Brain Tumor and Pituitary/Neuroendocrine Center at Lenox Hill, discusses various treatment options, highlights their differences, and provides guidance on how patients can talk with their heath team about their care plan. Watch here

 

Notable Clinical Publications & Awards

Journal of Neurosurgery Publication 2019
Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas 

David G. Brachman, MD, Emad Youssef, MD, Christopher J. Dardis, MD, Nader Sanai, MD, Joseph M. Zabramski, MD, Kris A. Smith, MD, Andrew S. Little, MD, Andrew G. Shetter, MD, Theresa Thomas, MS, Heyoung L. McBride, MD, MS, Stephen Sorensen, PhD, Robert F. Spetzler, MD, and Peter Nakaji, MDl, in the Journal of Neurosurgery. 2018;131:1683-1994. doi:10.3171/2018.7.jns18656

AANS Annual Scientific Meeting Abstracts 2019 – 2020
Rosenblum-Mahaley Clinical Award winner for the best abstract in the field of neuro-oncology 

Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial

Peter Nakaji, MD, FAANS; Emad Youssef, MD; Christopher Dardis, MD; Kris Smith, MD; Dilini Pinnaduwage, PhD; David Brachman, MD, at the 2019 AANS Meeting.

Novel permanently implanted 3D-collagen tile for intraoperative brachytherapy in a patient with recurrent glioblastoma 

Vincent Anthony DiNapoli, MD, Yair Gozal, MD, PhD, at the 2020 AANS Meeting.

American Brachytherapy Society Annual Meeting 2019
Judith Stitt Best Abstract Award winner 

Surgically targeted radiation therapy: safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial 

David Brachman, MD, Emad Youssef, MD, Christopher Dardis, MD, Kris Smith, MD, Dilini Pinnaduwage, PhD, Peter Nakaji, MD, in Brachytherapy. 2019;18(3):S35-S36. doi: 10.1016/j.brachy.2019.04.076.

SNO Annual Meeting Abstract 2019

RTHP-32. First experience with gamma tile permanent implants for recurrent brain tumors 
Clara Ferreira, Parham Alaei, Clark Chen, Margaret Reynolds, David Sterling, Kathryn Dusenbery, in Neuro-Oncology. 2019;21(Supplement_6):vi216. doi:10.1093/neuonc/noz175.903.

REFERENCES

  1. Nakaji P, Youssef E, Dardis C, Smith K, Pinnaduwage D, Brachman D. Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. Poster presented at: 2019 AANS Annual Scientific Meeting; April 2019; San Diego, CA.

  2. Chiu-Tsao ST, Napoli JJ, Davis SD, et al. Dosimetry for 131Cs and 125I seeds in solid water phantom using radiochromic EBT film. Appl Radiat Isot. 2014;92:102-114. 

  3. Pinnaduwage D, Youssef E, Sorensen S, Srivastava S, Yan X, Brachman D. Dosimetric impact of radioisotope type on permanent brain seed implants. Medical Physics. 2017;44(6):3146.

  4. Combs SE, Debus J, Schulz-Ertner D. Radiotheraputic alternatives for previously irradiated recurrent gliomas. BMC Cancer. 2007;7:167. 

  5. Wernicke AG, Smith AW, Taube S, et al. Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. J Neurosurg. 2017;126(4):1212-1219. 

  6. Magill ST, Lau D, Raleigh DR, Sneed PK, Fogh SE, McDermott MW. Surgical resection and interstitial iodine-125 brachytherapy for high-grade meningiomas: a 25-year series. Neurosurgery. 2017;80(3):409-416. 

  7. Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
    Int J Radiat Oncol Biol Phys. 2003;55(2):378-385.

GammaTile Therapy is indicated to deliver radiation therapy for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.

 

For full safety information, refer to the GammaTile Instructions for Use.

  • Twitter
  • LinkedIn
  • Facebook
  • YouTube

©2020 GT Medical Technologies, Inc.  I  All rights reserved  |   Instructions for Use  |  Privacy Policy

IMPROVING THE LIVES OF PATIENTS WITH BRAIN TUMORS